Pfizer Inc. and BioNTech said on Thursday they had asked U.S. regulators to approve emergency use of their COVID-19 vaccine for children aged from five to 11, Pfizer said in a post on Twitter.
“We and @BioNTech_Group officially submitted our request to @US_FDA for Emergency Use Authorization (EUA) of our #COVID19 vaccine in children 5 to <12,” the company said.
“We’re committed to working with the FDA with the ultimate goal of helping protect children against this serious public health threat.”
Pfizer has yet to make a full submission to Health Canada, but has sent in initial trial data to the Canadian regulator.
The company has previously said it hopes to make a full submission by mid-October.
(Reporting by Susan Heavey, Editing by Timothy Heritage)
— With files from Global News.
More Stories
Global measles cases nearly doubled in one year, researchers say
How to make conversations with aging parents a little less awkward | CBC Radio
N.S. mom calls for better ultrasound access after private clinic reveals twins | Globalnews.ca